LAURIA, ROSSELLA
 Distribuzione geografica
Continente #
NA - Nord America 977
EU - Europa 769
AS - Asia 213
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.975
Nazione #
US - Stati Uniti d'America 962
IT - Italia 419
CN - Cina 133
NL - Olanda 86
DE - Germania 77
UA - Ucraina 61
FR - Francia 45
FI - Finlandia 31
SG - Singapore 29
VN - Vietnam 26
IE - Irlanda 22
IN - India 22
CA - Canada 14
CI - Costa d'Avorio 13
GB - Regno Unito 13
SE - Svezia 7
EU - Europa 2
KR - Corea 2
RO - Romania 2
RS - Serbia 2
BZ - Belize 1
DK - Danimarca 1
IR - Iran 1
MK - Macedonia 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
Totale 1.975
Città #
Chandler 242
Amsterdam 86
Napoli 86
Millbury 59
Ashburn 53
Jacksonville 46
Beijing 41
Princeton 40
Nanjing 34
Naples 30
Dong Ket 24
Wilmington 20
Des Moines 19
Pune 16
Singapore 15
Milan 11
Tianjin 11
Boston 9
Lawrence 9
Ottawa 9
Falls Church 8
Nanchang 8
Shenyang 8
Redwood City 7
Rome 7
Ann Arbor 6
Casoria 6
Jiaxing 6
Rozzano 6
Leawood 5
Salerno 5
Seattle 5
Changsha 4
Dearborn 4
Fairfield 4
Menfi 4
San Mateo 4
Taizhou 4
Washington 4
Augusta 3
Battipaglia 3
Duncan 3
Hangzhou 3
Hebei 3
Jinan 3
Los Angeles 3
Pomigliano d'Arco 3
Serravalle Scrivia 3
Toronto 3
Villaricca 3
Boardman 2
Caserta 2
Castellammare Di Stabia 2
Catania 2
Cernusco sul Naviglio 2
Dallas 2
Hanoi 2
Kunming 2
Latina 2
Mariano Comense 2
Montauro 2
Mugnano Di Napoli 2
Mumbai 2
New York 2
Ningbo 2
Nola 2
Norwalk 2
Piove Di Sacco 2
Pregnana Milanese 2
Rapolla 2
Scafati 2
Suri 2
Teano 2
Andover 1
Ardabil 1
Arzano 1
Aversa 1
Bari 1
Belgrade 1
Belize City 1
Benevento 1
Bologna 1
Bozen 1
Caivano 1
Capena 1
Casalnuovo 1
Castelli Calepio 1
Castelvetrano 1
Centrale 1
Cesano 1
Cesenatico 1
Deiva Marina 1
Edinburgh 1
Esslingen am Neckar 1
Falkenstein 1
Florence 1
Forlì 1
Frattamaggiore 1
Fuzhou 1
Genoa 1
Totale 1.071
Nome #
null 223
Manuale di Oncologia Clinica 96
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 90
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 83
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 71
null 67
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 56
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 54
Decision making in borderline ovarian tumors: report of a rare case of mesosigma psammocarcinoma 44
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 44
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 43
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 41
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 41
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 40
Advanced and Locally unresectable gastric carcinoma: five years of survival with good quality of life. 39
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 39
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 39
CAVBP-DEP Altemative Chemotherapy for the treatment of intermediate and high grade non Hodgkin lymphoma: final results of a pilot study. 38
Chlorambucil, Vincristine and Cytarabine (COA) treatment of low grade lymphomas 38
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 37
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 36
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 35
Changing presentation in non Hodgkin lymphoma". 34
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 34
Tumor characteristics and prognosis in familial breast cancer 34
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 33
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 33
Bone involvement by adenocarcinoma of the uterine cervix: a rare entity 33
Tumor segmentation analysis at different post-contrast time points: A possible source of variability of quantitative DCE-MRI parameters in locally advanced breast cancer 33
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 32
Comparison of Tropisetron (ICS 205-930) with alizapride plus dexamethasone in the prevention of emesis induced by repeated cisplatin administration. 31
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 30
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 30
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 30
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 30
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 29
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 27
Partial deficiency of adrenal 11-hydroxylase: A possible cause of primary hypertension 27
Core curriculum. Oncologia clinica 27
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 25
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy. 24
Capitolo 15: i Tumori Ginecologici 24
'Primary Bone Lymphoma". 23
: Low dose dopamine induces early recovery of recombinant Interleukin-2 impaired renal function. 23
Tailored therapy for aggressive non-Hodgkin’s lymphoma: results of a phase II study with a long-term follow-up. 18
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. 18
Core curriculum. Oncologia clinica 18
Maintenance therapy with recombinant Interferon Alpha-2b (IFN) in prognostically in prognastically unfavourable aggressive non-Hodgkin’s lymphomas. 16
Salvage chemotherapy for non Hodgldn's lymphoma of unfavorable histology with a combination of CCNU and Vinblastine. 16
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 15
First-line systemic therapy for metastatic breast cancer and management of pleural effusion. 14
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety 9
Totale 2.064
Categoria #
all - tutte 7.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201927 0 0 0 0 0 0 0 0 0 0 10 17
2019/2020273 67 12 22 11 18 14 7 7 10 29 36 40
2020/2021267 8 12 31 29 29 26 26 8 34 3 32 29
2021/2022342 8 1 7 5 3 13 6 9 26 40 111 113
2022/2023523 57 65 18 42 57 54 3 39 74 92 16 6
2023/2024252 11 52 32 22 17 47 5 29 4 5 28 0
Totale 2.064